- Reports Revenue of $2.0 Billion, Growing 1%, and Net Income
of $552 Million, or $1.19 per Diluted Share, Decreasing 7% and 6%,
Respectively, on a Reported Basis for First Quarter 2023
- Delivers 4% Operational Growth in Revenue and a 3%
Operational Decline in Adjusted Net Income for First Quarter
2023
- Reports Adjusted Net Income of $607 Million, or Adjusted
Diluted EPS of $1.31, for First Quarter 2023
- Maintains Full Year 2023 Revenue Guidance of $8.575 - $8.725
Billion, with Diluted EPS of $5.03 to $5.14 on a Reported Basis, or
$5.34 to $5.44 on an Adjusted Basis
- Maintains Full-Year Operational Revenue Growth of 6% to 8%
and Full-Year Operational Growth in Adjusted Net Income of 7% to
9%
Zoetis Inc. (NYSE: ZTS) today reported its financial results for
the first quarter of 2023 and maintained its guidance for full year
2023.
The company reported revenue of $2.0 billion for the first
quarter of 2023, an increase of 1% compared with the first quarter
of 2022. On an operational1 basis, revenue for the first quarter of
2023 increased 4% compared with the first quarter of 2022,
excluding the impact of foreign currency. Net income for the first
quarter of 2023 was $552 million, or $1.19 per diluted share, a
decrease of 7% and 6%, respectively, on a reported basis.
Adjusted net income2 for the first quarter of 2023 was $607
million, or $1.31 per diluted share, which declined 3% and 1%,
respectively, on a reported and operational basis. Adjusted net
income for the first quarter of 2023 excludes the net impact of $55
million for purchase accounting adjustments, acquisition-related
costs and certain significant items.
EXECUTIVE COMMENTARY
“Today, we reported solid first-quarter results of 4%
operational growth in revenue, as expected, based on our diverse
portfolio and strength in international markets,” said Kristin
Peck, Chief Executive Officer of Zoetis. “Our International segment
led the way, growing revenue 10% operationally, and was partially
offset by a decline of 1% in the U.S. Our livestock portfolio drove
our results, with 12% operational growth in revenue, while
companion animal product revenues were flat operationally. The
performance in livestock was based on double-digit operational
growth for cattle, poultry, sheep and fish, while our U.S.
companion animal portfolio was impacted primarily by short-term
effects of distributors de-stocking."
“We continue to see strong end-market demand in companion animal
channels, based on data from veterinary clinics, retailers and pet
owners. While our sales into distributors declined in the quarter,
our product sales from distributors out to the veterinary clinics
were up approximately 8%3, affirming a healthy petcare market in
the U.S."
“We are reiterating our full-year guidance for operational
growth of 6% to 8% in revenue and 7% to 9% in adjusted net income.
Looking ahead, we see positive indicators and strong demand for our
animal health products, and we remain committed to delivering
strong growth in 2023, based on our market leadership, innovative
franchises, and diverse portfolio, while continuing to invest for
the future.”
QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its commercial operations across
two segments: United States (U.S.) and International. Within these
segments, the company delivers a diverse portfolio of products for
companion animals and livestock, tailored to local trends and
customer needs. In the first quarter of 2023:
- Revenue in the U.S. segment was $1.005 billion, a
decrease of 1% compared with the first quarter of 2022. Sales of
companion animal products decreased 7%, driven by distributor
de-stocking across the portfolio as well as higher purchases in the
fourth quarter of 2022 ahead of expected price increases and based
on promotional activities. Sales of livestock products increased
15% in the quarter. Sales of cattle products increased primarily
due to improved supply of key products as well as growth across our
beef implant portfolio, benefiting from expanded label approval in
re-implanting programs. The company’s poultry portfolio increased
due to expanded sales of vaccines despite a challenging economic
environment resulting from higher feed costs and the impact of
avian influenza on the commercial layer flock. This growth was
partially offset by a decrease in sales of swine products in the
quarter due to decreased disease prevalence.
- Revenue in the International segment was $978 million,
an increase of 3% on a reported basis and an increase of 10%
operationally compared with the first quarter of 2022. Sales of
companion animal products grew 3% on a reported basis and 10%
operationally. Contributing to growth in the quarter were the
company’s monoclonal antibody products for osteoarthritis pain —
Librela® for dogs and Solensia® for cats — as well as Simparica
Trio®. Also contributing to growth in the quarter was key
dermatology product Cytopoint® and feline vaccines. Sales of
livestock products grew 3% on a reported basis and 10%
operationally. Growth in the company’s cattle portfolio was the
result of increased sales in Australia and smaller emerging
markets. Sales of sheep products grew due to favorable market
conditions in Australia and the acquisition of Jurox. Sales of the
company’s poultry portfolio increased due to market growth and
demand generation efforts in several key geographies, while growth
in the fish portfolio was the result of increased sales of vaccines
across key salmon markets, primarily Norway.
INVESTMENTS IN GROWTH
Zoetis continues to grow key product franchises through
incremental claim extensions. Simparica Trio
(sarolaner/moxidectin/pyrantel), our triple combination oral
parasiticide, received approval in the European Union (EU) for
three new claims – prevention of eyeworms and efficacy against
sarcoptic and demodectic mange. Additionally, in Japan, the company
gained approvals for new indications of Cytopoint, our
monoclonal antibody for allergy treatment in dogs, and
anti-infective Draxxin® for pigs.
Zoetis also received approval in additional markets for new
livestock products. Protivity®, the first modified live
vaccine to offer protection against Mycoplasma bovis in healthy
cattle, was approved in the EU and Mexico (previously approved in
the U.S. and Canada), and Lawsotek™, a vaccine that helps
protect healthy pigs three weeks of age or older against disease
caused by the common bacterium Lawsonia intracellularis, was
approved in Canada (previously approved in the U.S.).
Additionally, the company recently purchased a manufacturing
site outside Atlanta, Georgia, which will be used to manufacture
monoclonal antibodies, vaccines and petcare products. The facility
will help ensure long-term supply of key product franchises across
all global markets and is expected to begin operations in 2026.
FINANCIAL GUIDANCE
Zoetis is maintaining its full year 2023 guidance, which
includes:
- Revenue between $8.575 billion to $8.725 billion (operational
growth of 6% to 8%)
- Reported net income between $2.345 billion to $2.400
billion
- Adjusted net income between $2.490 billion to $2.540 billion
(operational growth of 7% to 9%)
- Reported diluted EPS between $5.03 to $5.14
- Adjusted diluted EPS between $5.34 to $5.44
This guidance reflects foreign exchange rates as of late April.
Additional details on guidance are included in the financial tables
and will be discussed on the company's conference call this
morning.
WEBCAST & CONFERENCE CALL
DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (ET)
today, during which company executives will review first quarter
2023 results, discuss financial guidance and respond to questions
from financial analysts. Investors and the public may access the
live webcast by visiting the Zoetis website at
http://investor.zoetis.com/events-presentations. A replay of the
webcast will be archived and made available on May 4, 2023.
About Zoetis
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After innovating ways to predict,
prevent, detect, and treat animal illness for more than 70 years,
Zoetis continues to stand by those raising and caring for animals
worldwide -- from veterinarians and pet owners to livestock farmers
and ranchers. The company’s leading portfolio and pipeline of
medicines, vaccines, diagnostics and technologies make a difference
in over 100 countries. A Fortune 500 company, Zoetis generated
revenue of $8.1 billion in 2022 with approximately 13,800
employees. For more information, visit www.zoetis.com.
1 Operational growth (a non-GAAP financial measure) is defined
as growth excluding the impact of foreign exchange. 2 Adjusted net
income and its components and adjusted diluted earnings per share
(non-GAAP financial measures) are defined as reported net income
and reported diluted earnings per share, excluding purchase
accounting adjustments, acquisition-related costs and certain
significant items. 3Source: Animalytix Q1 2023 Animal Health
Industry Data Report
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to: business plans or
prospects, future operating or financial performance, future
guidance, future operating models; disruptions in our global supply
chain; R&D costs; timing and likelihood of success;
expectations regarding products, product approvals or products
under development and expected timing of product launches; the
impact of the coronavirus (COVID-19) global pandemic and any
recovery therefrom on our business, supply chain, customers and
employees; expectations regarding the performance of acquired
companies and our ability to integrate new businesses; expectations
regarding the financial impact of acquisitions; future use of cash,
dividend payments and share repurchases; tax rate and tax regimes
and any changes thereto; and other future events. These statements
are not guarantees of future performance or actions.
Forward-looking statements are subject to risks and uncertainties.
If one or more of these risks or uncertainties materialize, or if
management's underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a
forward-looking statement. Forward-looking statements speak only as
of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.
A further list and description of risks, uncertainties and other
matters can be found in our most recent Annual Report on Form 10-K,
including in the sections thereof captioned “Forward-Looking
Statements and Factors That May Affect Future Results” and “Item
1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our
Current Reports on Form 8-K. These filings and subsequent filings
are available online at www.sec.gov,
www.zoetis.com, or on request from
Zoetis.
Use of Non-GAAP Financial Measures:
We use non-GAAP financial measures, such as adjusted net income,
adjusted diluted earnings per share and operational results (which
exclude the impact of foreign exchange), to assess and analyze our
results and trends and to make financial and operational decisions.
We believe these non-GAAP financial measures are also useful to
investors because they provide greater transparency regarding our
operating performance. The non-GAAP financial measures included in
this press release should not be considered alternatives to
measurements required by GAAP, such as net income, operating
income, and earnings per share, and should not be considered
measures of liquidity. These non-GAAP financial measures are
unlikely to be comparable with non-GAAP information provided by
other companies. Reconciliations of non-GAAP financial measures and
the most directly comparable GAAP financial measures are included
in the tables accompanying this press release and are posted on our
website at www.zoetis.com.
Internet Posting of Information: We
routinely post information that may be important to investors in
the 'Investors' section of our website at www.zoetis.com, on our Facebook page at
http://www.facebook.com/zoetis and on
Twitter@zoetis. We encourage investors
and potential investors to consult our website regularly and to
follow us on Facebook and Twitter for important information about
us.
ZTS-COR
ZTS-IR
ZTS-FIN
ZOETIS INC. CONDENSED
CONSOLIDATED STATEMENTS OF INCOME(a) (UNAUDITED) (millions of
dollars, except per share data)
Three Months Ended
March 31,
2023
2022
% Change
Revenue
$
2,000
$
1,986
1
Costs and expenses:
Cost of sales
588
569
3
Selling, general and administrative
expenses
505
465
9
Research and development expenses
142
122
16
Amortization of intangible assets
37
41
(10)
Restructuring charges and certain
acquisition-related costs
21
2
*
Interest expense, net of capitalized
interest
63
53
19
Other (income)/deductions–net
(53)
7
*
Income before provision for taxes on
income
697
727
(4)
Provision for taxes on income
146
133
10
Net income before allocation to
noncontrolling interests
551
594
(7)
Less: Net loss attributable to
noncontrolling interests
(1)
(1)
—
Net income attributable to Zoetis Inc.
$
552
$
595
(7)
Earnings per share—basic
$
1.19
$
1.26
(6)
Earnings per share—diluted
$
1.19
$
1.26
(6)
Weighted-average shares used to calculate
earnings per share
Basic
463.5
472.2
Diluted
464.6
474.1
(a)The condensed consolidated statements
of income present the three months ended March 31, 2023 and 2022.
Subsidiaries operating outside the United States are included for
the three months ended February 28, 2023 and 2022.
* Calculation not meaningful.
ZOETIS INC. RECONCILIATION OF
GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS
(UNAUDITED) (millions of dollars, except per share data)
Three Months Ended March 31,
2023
GAAP Reported(a)
Purchase Accounting
Adjustments
Acquisition- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(b)
Cost of sales
$
588
$
(4)
$
—
$
—
$
584
Gross profit
1,412
4
—
—
1,416
Selling, general and administrative
expenses
505
(7)
—
—
498
Amortization of intangible assets
37
(31)
—
—
6
Restructuring charges and certain
acquisition-related costs
21
—
(1)
(20)
—
Other (income)/deductions–net
(53)
—
—
(2)
(55)
Income before provision for taxes on
income
697
42
1
22
762
Provision for taxes on income
146
8
—
2
156
Net income attributable to Zoetis
552
34
1
20
607
Earnings per common share attributable to
Zoetis–diluted
1.19
0.07
—
0.05
1.31
Three Months Ended March 31,
2022
GAAP Reported(a)
Purchase Accounting
Adjustments
Acquisition- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(b)
Cost of sales
$
569
$
(1)
$
—
$
(3)
$
565
Gross profit
1,417
1
—
3
1,421
Selling, general and administrative
expenses
465
(7)
—
—
458
Amortization of intangible assets
41
(32)
—
—
9
Restructuring charges and certain
acquisition-related costs
2
—
(2)
—
—
Other (income)/deductions–net
7
—
—
3
10
Income before provision for taxes on
income
727
40
2
—
769
Provision for taxes on income
133
10
1
1
145
Net income attributable to Zoetis
595
30
1
(1)
625
Earnings per common share attributable to
Zoetis–diluted
1.26
0.06
—
—
1.32
(a) The condensed consolidated statements
of income present the three months ended March 31, 2023 and 2022.
Subsidiaries operating outside the United States are included for
the three months ended February 28, 2023 and 2022.
(b) Non-GAAP adjusted net income and its
components and non-GAAP adjusted diluted EPS are not, and should
not be viewed as, substitutes for U.S. GAAP net income and its
components and diluted EPS. Despite the importance of these
measures to management in goal setting and performance measurement,
non-GAAP adjusted net income and its components and non-GAAP
adjusted diluted EPS are non-GAAP financial measures that have no
standardized meaning prescribed by U.S. GAAP and, therefore, have
limits in their usefulness to investors. Because of the
non-standardized definitions, non-GAAP adjusted net income and its
components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net
income and its components and diluted EPS) may not be comparable to
the calculation of similar measures of other companies. Non-GAAP
adjusted net income and its components, and non-GAAP adjusted
diluted EPS are presented solely to permit investors to more fully
understand how management assesses performance.
See Notes to Reconciliation of GAAP
Reported to Non-GAAP Adjusted Information for notes (1) and
(2).
ZOETIS INC. NOTES TO
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars)
(1) Acquisition-related costs include the
following:
Three Months Ended
March 31,
2023
2022
Integration costs(a)
$
1
$
2
Total acquisition-related
costs—pre-tax
1
2
Income taxes(b)
—
1
Total acquisition-related costs—net of
tax
$
1
$
1
(a) Integration costs represent external,
incremental costs directly related to integrating acquired
businesses and primarily include expenditures for consulting and
the integration of systems and processes. Included in Restructuring
charges and certain acquisition-related costs.
(b) Included in Provision for taxes on
income. Income taxes include the tax effect of the associated
pre-tax amounts, calculated by determining the jurisdictional
location of the pre-tax amounts and applying that jurisdiction's
applicable tax rate.
(2) Certain significant items include the
following:
Three Months Ended
March 31,
2023
2022
Other restructuring charges and
cost-reduction/productivity initiatives(a)
$
20
$
2
Other
2
(2)
Total certain significant
items—pre-tax
22
—
Income taxes(b)
2
1
Total certain significant items—net of
tax
$
20
$
(1)
(a) For the three months ended March 31,
2023, primarily consisted of employee termination costs related to
organizational structure refinements, included in Restructuring
charges and certain acquisition-related costs.
For the three months ended March 31, 2022,
primarily consisted of product transfer costs, included in Cost of
sales.
(b) Included in Provision for taxes on
income. Income taxes include the tax effect of the associated
pre-tax amounts, calculated by determining the jurisdictional
location of the pre-tax amounts and applying that jurisdiction's
applicable tax rate.
ZOETIS INC. ADJUSTED SELECTED
COSTS, EXPENSES AND INCOME(a) (UNAUDITED) (millions of dollars)
Three Months Ended
March 31,
% Change
2023
2022
Total
Foreign Exchange
Operational(b)
Adjusted cost of sales
$
584
$
565
3 %
(9) %
12 %
as a percent of revenue
29.2 %
28.4 %
NA
NA
NA
Adjusted SG&A expenses
498
458
9 %
(2) %
11 %
Adjusted R&D expenses
142
122
16 %
(3) %
19 %
Adjusted net income attributable to
Zoetis
607
625
(3) %
— %
(3) %
(a) Adjusted cost of sales, adjusted
selling, general, and administrative (SG&A) expenses, adjusted
research and development (R&D) expenses, and adjusted net
income (non-GAAP financial measures) are defined as the
corresponding reported U.S. GAAP income statement line items
excluding purchase accounting adjustments, acquisition-related
costs and certain significant items. These adjusted income
statement line item measures are not, and should not be viewed as,
substitutes for the corresponding U.S. GAAP line items. The
corresponding GAAP line items and reconciliations of reported to
adjusted information are provided in Condensed Consolidated
Statements of Income and Reconciliation of GAAP Reported to
Non-GAAP Adjusted Information.
(b) Operational growth (a non-GAAP
financial measure) is defined as growth excluding the impact of
foreign exchange.
ZOETIS INC. 2023 GUIDANCE
Selected Line Items (millions of dollars,
except per share amounts)
Full Year 2023
Revenue
$8,575 to $8,725
Operational growth(a)
6% to 8%
Adjusted cost of sales as a percentage of
revenue(b)
29.5% to 30.0%
Adjusted SG&A expenses(b)
$2,060 to $2,100
Adjusted R&D expenses(b)
$635 to $660
Adjusted interest expense and other
(income)/deductions-net(b)
Approximately $170
Effective tax rate on adjusted
income(b)
20.0% to 21.0%
Adjusted diluted EPS(b)
$5.34 to $5.44
Adjusted net income(b)
$2,490 to $2,540
Operational growth(a)(c)
7% to 9%
Certain significant items and
acquisition-related costs(d)
$20 - $25
The guidance reflects foreign exchange
rates as of late April 2023.
Reconciliations of 2023 reported guidance
to 2023 adjusted guidance follows:
(millions of dollars, except per share amounts)
Reported
Certain significant items and
acquisition-related costs(d)
Purchase accounting
Adjusted(c)
Cost of sales as a percentage of
revenue
29.7% to 30.2%
~ (0.1%)
~ (0.1%)
29.5% to 30.0%
SG&A expenses
$2,090 to $2,130
~ $(30)
$2,060 to $2,100
R&D expenses
$636 to $661
~ $(1)
$635 to $660
Interest expense and other
(income)/deductions-net
~ $170
~ $170
Effective tax rate
20.0% to 21.0%
20.0% to 21.0%
Diluted EPS
$5.03 to $5.14
$0.04 - $0.05
~ $0.26
$5.34 to $5.44
Net income attributable to Zoetis
$2,345 to $2,400
$20 - $25
~ $120
$2,490 to $2,540
(a) Operational growth (a non-GAAP
financial measure) excludes the impact of foreign exchange.
(b) Adjusted net income and its components
and adjusted diluted EPS are defined as reported U.S. GAAP net
income and its components and reported diluted EPS excluding
purchase accounting adjustments, acquisition-related costs and
certain significant items. Adjusted cost of sales, adjusted
SG&A expenses, adjusted R&D expenses, and adjusted interest
expense and other (income)/deductions-net are income statement line
items prepared on the same basis, and, therefore, components of the
overall adjusted income measure. Despite the importance of these
measures to management in goal setting and performance measurement,
adjusted net income and its components and adjusted diluted EPS are
non-GAAP financial measures that have no standardized meaning
prescribed by U.S. GAAP and, therefore, have limits in their
usefulness to investors. Because of the non-standardized
definitions, adjusted net income and its components and adjusted
diluted EPS (unlike U.S. GAAP net income and its components and
diluted EPS) may not be comparable to the calculation of similar
measures of other companies. Adjusted net income and its components
and adjusted diluted EPS are presented solely to permit investors
to more fully understand how management assesses performance.
Adjusted net income and its components and adjusted diluted EPS are
not, and should not be viewed as, substitutes for U.S. GAAP net
income and its components and diluted EPS.
(c) We do not provide a reconciliation of
forward-looking non-GAAP adjusted net income operational growth to
the most directly comparable U.S. GAAP reported financial measure
because we are unable to calculate with reasonable certainty the
foreign exchange impact of unusual gains and losses,
acquisition-related expenses, potential future asset impairments
and other certain significant items, without unreasonable effort.
The foreign exchange impacts of these items are uncertain, depend
on various factors, and could have a material impact on U.S. GAAP
reported results for the guidance period.
(d) Primarily includes certain
nonrecurring costs related to acquisitions and other charges.
ZOETIS INC.
CONSOLIDATED REVENUE BY
SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
Three Months Ended
March 31,
% Change
2023
2022
Total
Foreign Exchange
Operational(b)
Revenue:
Companion Animal
$
1,225
$
1,263
(3) %
(3) %
— %
Livestock
758
705
8 %
(4) %
12 %
Contract Manufacturing & Human
Health
17
18
(6) %
(2) %
(4) %
Total Revenue
$
2,000
$
1,986
1 %
(3) %
4 %
U.S.
Companion Animal
$
721
$
774
(7) %
— %
(7) %
Livestock
284
246
15 %
— %
15 %
Total U.S. Revenue
$
1,005
$
1,020
(1) %
— %
(1) %
International
Companion Animal
$
504
$
489
3 %
(7) %
10 %
Livestock
474
459
3 %
(7) %
10 %
Total International Revenue
$
978
$
948
3 %
(7) %
10 %
Companion Animal:
Dogs and Cats
$
1,153
$
1,199
(4) %
(3) %
(1) %
Horses
72
64
13 %
(3) %
16 %
Total Companion Animal Revenue
$
1,225
$
1,263
(3) %
(3) %
— %
Livestock:
Cattle
$
399
$
364
10 %
(3) %
13 %
Swine
142
154
(8) %
(5) %
(3) %
Poultry
139
124
12 %
(5) %
17 %
Fish
49
44
11 %
(7) %
18 %
Sheep and other
29
19
53 %
(8) %
61 %
Total Livestock Revenue
$
758
$
705
8 %
(4) %
12 %
(a) For a description of each segment, see
Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue growth (a non-GAAP
financial measure) is defined as revenue growth excluding the
impact of foreign exchange.
ZOETIS INC.
CONSOLIDATED REVENUE BY KEY
INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
Three Months Ended
March 31,
% Change
2023
2022
Total
Foreign Exchange
Operational(a)
Total International
$
977.5
$
947.5
3 %
(7) %
10 %
Australia
81.8
64.9
26 %
(6) %
32 %
Brazil
84.0
76.8
9 %
5 %
4 %
Canada
50.1
49.0
2 %
(6) %
8 %
Chile
39.2
41.2
(5) %
— %
(5) %
China
102.2
102.7
— %
(8) %
8 %
France
33.7
31.9
6 %
(6) %
12 %
Germany
45.3
43.1
5 %
(6) %
11 %
Italy
25.5
30.4
(16) %
(5) %
(11) %
Japan
39.1
59.1
(34) %
(11) %
(23) %
Mexico
38.6
34.8
11 %
8 %
3 %
Spain
32.9
33.4
(1) %
(5) %
4 %
United Kingdom
68.2
63.5
7 %
(12) %
19 %
Other developed markets
121.9
115.2
6 %
(7) %
13 %
Other emerging markets
215.0
201.5
7 %
(13) %
20 %
(a) Operational revenue growth (a non-GAAP
financial measure) is defined as revenue growth excluding the
impact of foreign exchange.
ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
Three Months Ended
March 31,
% Change
2023
2022
Total
Foreign Exchange
Operational(b)
U.S.:
Revenue
$
1,005
$
1,020
(1) %
— %
(1) %
Cost of Sales
203
185
10 %
— %
10 %
Gross Profit
802
835
(4) %
— %
(4) %
Gross Margin
79.8 %
81.9 %
Operating Expenses
188
165
14 %
— %
14 %
Other (income)/deductions-net
—
—
*
*
*
U.S. Earnings
$
614
$
670
(8) %
— %
(8) %
International:
Revenue
$
978
$
948
3 %
(7) %
10 %
Cost of Sales
291
265
10 %
(10) %
20 %
Gross Profit
687
683
1 %
(5) %
6 %
Gross Margin
70.2 %
72.0 %
Operating Expenses
151
145
4 %
(7) %
11 %
Other (income)/deductions-net
1
—
*
*
*
International Earnings
$
535
$
538
(1) %
(5) %
4 %
Total Reportable Segments
$
1,149
$
1,208
(5) %
(2) %
(3) %
Other business activities(c)
(114)
(98)
16 %
Reconciling Items:
Corporate(d)
(208)
(259)
(20) %
Purchase accounting adjustments(e)
(42)
(40)
5 %
Acquisition-related costs(f)
(1)
(2)
(50) %
Certain significant items(g)
(22)
—
*
Other unallocated(h)
(65)
(82)
(21) %
Total Earnings(i)
$
697
$
727
(4) %
(a) For a description of each segment, see
Zoetis' most recent Annual Report on Form 10-K.
(b) Operational growth (a non-GAAP
financial measure) is defined as growth excluding the impact of
foreign exchange.
(c) Other business activities includes the
research and development costs managed by our research and
development organization, as well as our contract manufacturing
business and human health business.
(d) Corporate includes, among other
things, certain costs associated with information technology,
administration expenses, interest income and expense, certain
compensation costs and other costs not charged to our operating
segments.
(e) Purchase accounting adjustments
include certain charges related to the amortization of fair value
adjustments to inventory, intangible assets and property, plant and
equipment not charged to our operating segments.
(f) Acquisition-related costs include
costs associated with acquiring and integrating newly acquired
businesses, such as transaction costs and integration costs.
(g) Certain significant items includes
substantive, unusual items that, either as a result of their nature
or size, would not be expected to occur as part of our normal
business on a regular basis. Such items primarily include certain
asset impairment charges, restructuring charges and implementation
costs associated with cost-reduction/productivity initiatives that
are not associated with an acquisition and the impact of
divestiture-related gains and losses.
(h) Includes overhead expenses associated
with our global manufacturing and supply operations not directly
attributable to an operating segment, as well as certain
procurement costs.
(i) Defined as income before provision for
taxes on income.
* Calculation not meaningful.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005746/en/
Media Contacts: Bill Price
1-973-443-2742 (o) william.price@zoetis.com Kristen Seely
1-973-443-2777 (o) kristen.seely@zoetis.com
Investor Contact: Steve Frank
1-973-822-7141 (o) steve.frank@zoetis.com Nick Soonthornchai
1-973-443-2792 (o) nick.soonthornchai@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Apr 2023 to Apr 2024